Diabetes with poor glycaemic control does not promote atherosclerosis in genetically modified hypercholesterolaemic minipigs

[1]  A. Rosengren,et al.  Glycemic control and excess mortality in type 1 diabetes. , 2014, The New England journal of medicine.

[2]  W. Ahmad.  Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus The AleCardio Randomized Clinical Trial , 2014 .

[3]  Lars Bolund,et al.  Familial Hypercholesterolemia and Atherosclerosis in Cloned Minipigs Created by DNA Transposition of a Human PCSK9 Gain-of-Function Mutant , 2013, Science Translational Medicine.

[4]  D. Accili,et al.  Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice. , 2012, The Journal of clinical investigation.

[5]  B. Hemmingsen.  Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus , 2011, The Cochrane database of systematic reviews.

[6]  Shih-Jen Hwang,et al.  Predictors of incident albuminuria in the Framingham Offspring cohort. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  E. Falk,et al.  Atherosclerotic lesions in mouse and man: is it the same disease? , 2010, Current opinion in lipidology.

[8]  M. Keane,et al.  Akt pathway is hypoactivated by synergistic actions of diabetes mellitus and hypercholesterolemia resulting in advanced coronary artery disease. , 2010, American journal of physiology. Heart and circulatory physiology.

[9]  Baqiyyah N. Conway,et al.  Is glycaemia or insulin dose the stronger risk factor for coronary artery disease in type 1 diabetes? , 2009, Diabetes & vascular disease research.

[10]  W. Blaner,et al.  Decreased Lipoprotein Clearance Is Responsible for Increased Cholesterol in LDL Receptor Knockout Mice With Streptozotocin-Induced Diabetes , 2008, Diabetes.

[11]  B. Zinman,et al.  Type 1 diabetes, hyperglycaemia, and the heart , 2008, The Lancet.

[12]  R. Klein,et al.  Association between glycosylated hemoglobin level and cardiovascular and all-cause mortality in type 1 diabetes. , 2007, American journal of epidemiology.

[13]  E. Tuzcu,et al.  Intracoronary ultrasound examinations reveal significantly more advanced coronary atherosclerosis in people with type 1 diabetes than in age- and sex-matched non-diabetic controls , 2007, Diabetes & vascular disease research.

[14]  David M Nathan,et al.  The Effect of Intensive Glycemic Treatment on Coronary Artery Calcification in Type 1 Diabetic Participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study , 2006, Diabetes.

[15]  P. Nestel,et al.  The cis-9,trans-11 isomer of conjugated linoleic acid (CLA) lowers plasma triglyceride and raises HDL cholesterol concentrations but does not suppress aortic atherosclerosis in diabetic apoE-deficient mice. , 2006, Atherosclerosis.

[16]  B. Zinman,et al.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. , 2005, The New England journal of medicine.

[17]  Mengwei Zang,et al.  The Thromboxane A2 Receptor Antagonist S18886 Prevents Enhanced Atherogenesis Caused by Diabetes Mellitus , 2005, Circulation.

[18]  A. Rábano,et al.  Development of atherosclerosis in the diabetic BALB/c mice. Prevention with Vitamin E administration. , 2005, Atherosclerosis.

[19]  M. Cooper,et al.  Rosiglitazone Attenuates Atherosclerosis in a Model of Insulin Insufficiency Independent of Its Metabolic Effects , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[20]  P. Libby,et al.  Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. , 2005, Circulation.

[21]  Y. Yamaguchi,et al.  Overexpression of Hyaluronan in the Tunica Media Promotes the Development of Atherosclerosis , 2005, Circulation research.

[22]  A. Chait,et al.  Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. , 2004, The Journal of clinical investigation.

[23]  I. Goldberg.  Why does diabetes increase atherosclerosis? I don't know! , 2004, The Journal of clinical investigation.

[24]  N. Chaturvedi,et al.  Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study. , 2004, Diabetes care.

[25]  M. Sturek,et al.  Increased atherosclerosis in diabetic dyslipidemic swine: protection by atorvastatin involves decreased VLDL triglycerides but minimal effects on the lipoprotein profile. , 2002, Journal of lipid research.

[26]  M. Halks-Miller,et al.  Reduction of cardiac functional reserve and elevation of aortic stiffness in hyperlipidemic Yucatan minipigs with systemic and coronary atherosclerosis. , 2002, Vascular pharmacology.

[27]  A. Tall,et al.  Lipoprotein lipase deficiency and CETP in streptozotocin-treated apoB-expressing mice. , 2002, Journal of lipid research.

[28]  K. Forrest,et al.  Glycemia (or, in women, estimated glucose disposal rate) predict lower extremity arterial disease events in type 1 diabetes. , 2002, Metabolism: clinical and experimental.

[29]  R. Natarajan,et al.  Diabetes-induced accelerated atherosclerosis in swine. , 2001, Diabetes.

[30]  L. Kuller,et al.  Coronary calcium in adults with type 1 diabetes: a stronger correlate of clinical coronary artery disease in men than in women. , 2000, Diabetes.

[31]  J. George,et al.  Effect of hyperglycemia and hyperlipidemia on atherosclerosis in LDL receptor-deficient mice: establishment of a combined model and association with heat shock protein 65 immunity. , 2000, Diabetes.

[32]  R. Virmani,et al.  Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[33]  M. Schwartz,et al.  Effects of streptozotocin-induced diabetes and insulin treatment on the hypothalamic melanocortin system and muscle uncoupling protein 3 expression in rats. , 2000, Diabetes.

[34]  M. Sturek,et al.  Dyslipidemia and vascular dysfunction in diabetic pigs fed an atherogenic diet. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[35]  Y. Kako,et al.  Streptozotocin-induced diabetes in human apolipoprotein B transgenic mice. Effects on lipoproteins and atherosclerosis. , 1999, Journal of lipid research.

[36]  A. Schmidt,et al.  Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts , 1998, Nature Medicine.

[37]  P. Reaven,et al.  Effect of streptozotocin-induced hyperglycemia on lipid profiles, formation of advanced glycation endproducts in lesions, and extent of atherosclerosis in LDL receptor-deficient mice. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[38]  D. L. Wilson,et al.  Increased atherosclerosis in streptozotocin-induced diabetic mice. , 1996, The Journal of clinical investigation.

[39]  J. D. Karkas,et al.  Intestinal and Hepatic Cholesterogenesis in Hypercholesterolemic Dyslipidemia of Experimental Diabetes in Dogs , 1991, Diabetes.

[40]  D. McNamara,et al.  Contributions of Absorbed Dietary Cholesterol and Cholesterol Synthesized in Small Intestine to Hypercholesterolemia in Diabetic Rats , 1988, Diabetes.

[41]  B. Nordestgaard,et al.  Reduced Atherogenesis in Cholesterol‐fed Diabetic Rabbits: Giant Lipoproteins Do Not Enter the Arterial Wall , 1988, Arteriosclerosis.

[42]  A. Soutar,et al.  Hormonal regulation of low-density lipoprotein (LDL) receptor activity in human hepatoma Hep G2 cells. Insulin increases LDL receptor activity and diminishes its suppression by exogenous LDL. , 1988, European journal of biochemistry.

[43]  H. D. Kim,et al.  Studies on the energy metabolism of pig red cells. I. The limiting role of membrane permeability in glycolysis. , 1971, Biochimica et biophysica acta.

[44]  J. Shaw,et al.  Glycemic control and excess mortality in type 1 diabetes. , 2015, The New England journal of medicine.

[45]  W. J. van der Giessen,et al.  Coronary microvascular dysfunction in a porcine model of early atherosclerosis and diabetes. , 2012, American journal of physiology. Heart and circulatory physiology.

[46]  J. Breslow,et al.  Effects of streptozotocin-induced diabetes in apolipoprotein AI deficient mice. , 2004, Atherosclerosis.

[47]  John M. Lachin,et al.  Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. , 2003, JAMA.

[48]  Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. , 1995, The American journal of cardiology.